Cabio Biotech Wuhan Co Ltd688089
Mentioned
Jiabei You disclosed its earnings forecast, expecting a net loss attributable to the parent company of 101 million yuan in the first half of 2026, compared to a profit of 108 million yuan in the same period last year. The company's operating revenue for the period is expected to be 55 million yuan, a year-on-year decline of 82.07 percent. The non-recurring net loss is 99.9702 million yuan, compared to a profit of 99.9228 million yuan in the same period last year. The sharp decline in performance is mainly due to adjustments in production plans caused by overseas market sentiment and new regulatory requirements, with product production and sales not yet fully recovered.
Cabio Biotech Wuhan Co Ltd